This study determined the prevalence of Group B Streptococcus (GBS) in late pregnancy and the antimicrobial susceptibility of isolated GBS as well as the impact of GBS infections on pregnancy related clinical outcome with a view of providing an epidemiological baseline data for policy formulation in the teaching hospital. It is an observational and cross-sectional hospital based study. One hundred and fifty pregnant women from 35-40 weeks of gestation were purposively selected and included in the study from May to December 2010. Vaginal swab samples were aseptically collected from the subjects after informed consent. The samples were assayed for presence of GBS. The susceptibility pattern of the isolated GBS to different antibiotics were assessed using disc diffusion and agar dilution techniques based on the Clinical and Laboratory Standards institute(CLSI) standards. The result showed prevalence of 11.3% GBS vaginal colonization which increased with age. There was no significant association between GBS colonization status and age (p >0.05)), gestational age (p >0.05)), gravidity (p >0.05) and obstetric risk factors (p >0.05)). There was no incidence of GBS infection observed. Although, all (17) the GBS isolates were 100% resistance to penicillin, ampicillin, cefoxitin and clindamycin. Resistance to cefotaxime (11.8%), erythromycin (64.7%) and vancomycin 70.6% were observed. Group B Streptococcus colonization in vagina in late pregnancy has been established in the antenatal clinic of the teaching hospital with the attendant risk to the fetus in the population of those affected. There were high and multiple resistance patterns of the GBS isolates to different antibiotics in this study. This calls for a review of the present hospital policy to include the routine screening of GBS during antenatal visits and surveillance.

patients who were confirmed with COVID-19 postoperatively (20.4%) compared with preoperatively (9.1%). Care and staffing needs differ, so preoperative COVID-19 testing and diagnoses can be helpful to ensure needs are met before complications arise. Strategies can be implemented to address more emergent surgeries where prior testing is not feasible. When making discussions, the mother, neonate, and HCWs should be considered to minimize risk and improve safety for all involved. Future research and studies should look at the clinical benefits and risks of the testing pathway, PPE use and its impact on HCW outcomes, and risks and benefits of maternal-neonate interaction after the mother tests positive for COVID-19.

No abstract

The members of the writing committee assume responsibility for the overall content and integrity of this article. The full names, academic degrees, and affiliations of the members of the writing committee are listed in the Appendix.

Background Preterm birth or low birth weight is the single largest cause of death in newborns, however this mortality can be reduced through newborn care interventions, including Kangaroo Mother Care (KMC). Previously, a multi-country randomized controlled trial, coordinated by the World Health Organization (WHO), reported a significant survival advantage with initiation of continuous KMC immediately after birth compared with initiation of continuous KMC a few days after birth when the baby is considered clinically stable. Whether the survival advantage would lead to higher rates of neurodevelopmental morbidities, or the immediate KMC will also have a beneficial effect on cognitive development also, has not been investigated. We therefore propose to test the hypothesis that low-birth-weight infants exposed to immediate KMC will have lower rates of neurodevelopmental impairment in comparison to traditional KMC-treated infants, by prospectively following up infants already enrolled in the immediate KMC trial for the first 2 years of life, and assessing their growth and neurodevelopment. Methods This prospective cohort study will enroll surviving neonates from the main WHO immediate KMC trial. The main trial as well as this follow-up study are being conducted in five low- and middle-income countries in South Asia and sub-Saharan Africa. The estimated sample size for comparison of the risk of neurodevelopmental impairment is a total of 2200 children. The primary outcome will include rates of cerebral palsy, hearing impairment, vision impairment, mental and motor development, and epilepsy and will be assessed by the age of 3 years. The analysis will be by intention to treat. Discussion Immediate KMC can potentially reduce low-birth-weight-associated complications such as respiratory disease, hypothermia, hypoglycemia, and infection that can result in impaired neurocognitive development. Neuroprotection may also be mediated by improved physiological stabilization that may lead to better maturation of neural pathways, reduced risk of hypoxia, positive parental impact, improved sleep cycles, and improved stress responses. The present study will help in evaluating the overall impact of KMC by investigating the long-term effect on neurodevelopmental impairment in the survivors. Trial registration Clinical Trials Registry-India CTRI/2019/11/021899. Registered on 06 November 2019. Trials registration of parent trial: ACTRN12618001880235; Clinical Trials Registry-India: CTRI/2018/08/015369.